- Conditions
- Macular Degeneration
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 289
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Biological
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 69
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Arcadia, California + 61 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- SF0166 Topical Ophthalmic Solution
- Drug
- Lead sponsor
- OcuTerra Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Fullerton, California • Mountain View, California + 9 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Intravitreal Aflibercept Injection 2mg
- Drug
- Lead sponsor
- Tennessee Retina
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Age Related Macular Degeneration
- Interventions
- Subretinally injected RetinoStat
- Drug
- Lead sponsor
- Oxford BioMedica
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- AM712(ASKG712)
- Biological
- Lead sponsor
- AffaMed Therapeutics Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Poway, California • Walnut Creek, California • Lakewood, Colorado + 6 more
- Conditions
- Macular Degeneration
- Interventions
- bevasiranib, ranibizumab
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fresno, California + 47 more
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
- Interventions
- MHU650
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Ranibizumab 0.5mg
- Drug
- Lead sponsor
- Leonard Feiner, MD, PhD
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Teaneck, New Jersey • Vauxhall, New Jersey
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- SOK583A1 (40 mg/mL), Eylea EU (40 mg/mL)
- Biological
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Arcadia, California • Campbell, California + 25 more
- Conditions
- Exudative Age Related Macular Degeneration
- Interventions
- Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, verteporfin
- Drug · Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 50 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Age-Related Macular Degeneration
- Interventions
- 0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122, 4.0 mg of DE-122
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 5
- States / cities
- Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
- Interventions
- AIV007
- Drug
- Lead sponsor
- AiViva BioPharma, Inc.
- Industry
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Santa Ana, California • Eugene, Oregon + 3 more
- Conditions
- Low Vision, Neovascular Age-related Macular Degeneration
- Interventions
- Vision rehabilitation
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years to 105 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Interventions
- Tiespectus, Aflibercept
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 9
- States / cities
- Mountain View, California • Lemont, Illinois • Hagerstown, Maryland + 6 more
- Conditions
- Macular Degeneration
- Interventions
- AdGVPEDF.11D
- Drug
- Lead sponsor
- GenVec
- Industry
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 9
- States / cities
- Beverly Hills, California • Los Angeles, California • Boynton Beach, Florida + 5 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- OTX-TKI (axitinib implant), Aflibercept
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 97
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 81 more
- Conditions
- Choroidal Neovascularization, Age-Related Macular Degeneration
- Interventions
- Periocular injection of triamcinolone acetonide 40mg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Portland, Oregon
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- OTX-TKI/Sham, Aflibercept/Sham
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Bakersfield, California • Oxnard, California • Altamonte Springs, Florida + 3 more
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascular Membrane, Subfoveal Neovascular Age-Related Macular Degeneration, Macular Degeneration, Wet Age-Related Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- David M. Brown, M.D.
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Houston, Texas • The Woodlands, Texas
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Interventions
- Optical Coherence Tomography
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Age-Related Macular Degeneration, Neovascularization, Choroidal
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 73 participants
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Macular Degeneration
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Beverly Hills, California • Pasadena, California + 13 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal Injections of 10 mg/mL Ranibizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 77
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 66 more